Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Cipla
Boehringer Ingelheim
US Department of Justice
US Army
Chubb
QuintilesIMS

Generated: May 19, 2019

DrugPatentWatch Database Preview

AVEED Drug Profile

« Back to Dashboard

Which patents cover Aveed, and when can generic versions of Aveed launch?

Aveed is a drug marketed by Endo Pharms Inc and is included in one NDA. There are two patents protecting this drug and one Paragraph IV challenge.

This drug has fifty-one patent family members in thirty-seven countries.

The generic ingredient in AVEED is testosterone undecanoate. There are sixty-nine drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the testosterone undecanoate profile page.

Drug patent expirations by year for AVEED
Generic Entry Opportunity Date for AVEED
Generic Entry Date for AVEED*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
INJECTABLE;INTRAMUSCULAR

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for AVEED
Drug ClassAndrogen
Mechanism of ActionAndrogen Receptor Agonists
Synonyms for AVEED
(17-beta)-3-Oxoandrost-4-en-17-yl undecanoate
(17|A)-17-[(1-| xoundecyl)oxy]androst-4-en-3-one
(17beta)-3-Oxoandrost-4-en-17-yl undecanoate
(1S,2R,10R,11S,14S,15S)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadec-6-en-14-yl undecanoate
(1S,2R,10R,11S,14S,15S)-2,15-dimethyl-5-oxotetracyclo[8.7.0.0?,?.0??,??]heptadec-6-en-14-yl undecanoate
[(8R,9S,10R,13S,14S,17S)-10,13-dimethyl-3-oxo-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl] undecanoate
17beta-Hydroxyandrost-4-en-3-one undecanoate
3-Oxoandrost-4-en-17beta-yl undecanoate
4-08-00-00981 (Beilstein Handbook Reference)
5-.alpha.-Androstan-3-one, 17-.beta.-hydroxy-, undecanoate
5-alpha-Androstan-3-one, 17-beta-hydroxy-, undecanoate
5949-44-0
949T440
AC1L22PV
AKOS016010255
AN-11881
Andriol
Andriol (TN)
Andriol Testocaps
Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17-beta)-
Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-, (17beta)-
Androst-4-en-3-one, 17-((1-oxoundecyl)oxy)-(17beta)
Androst-4-en-3-one, 17-[(1-oxoundecyl)oxy]-, (17.beta.)-
BAY 86-5037
BCP11921
BRN 3176734
C-22555
CC-34823
CHEBI:135741
CHEMBL2107067
CLR-610
CS-4342
D06087
EINECS 227-712-6
GS-6598
H16A5VCT9C
HY-B0626
Jatenzo
LS-148824
MolPort-003-850-422
Nebido
Nebido-R
Org 538
ORG-538
Pantestone
Reandron 1000
Restandol
Rextoro
SC-16124
SCHEMBL147620
T undecanoate
Testosterone (undecanoate)
Testosterone undecanoate
Testosterone undecanoate (USAN)
Testosterone undecanoate [USAN]
Testosterone Undeconate
Testosterone undecylate
Testosterone, undecanoate
Testosterone, undecanoate (ester)
UDSFVOAUHKGBEK-CNQKSJKFSA-N
Undestor
UNII-H16A5VCT9C
W-105318
ZINC8214690

US Patents and Regulatory Information for AVEED

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Endo Pharms Inc AVEED testosterone undecanoate INJECTABLE;INTRAMUSCULAR 022219-001 Mar 5, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Endo Pharms Inc AVEED testosterone undecanoate INJECTABLE;INTRAMUSCULAR 022219-001 Mar 5, 2014 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

Subscribe to access the full database, or try a Free Trial

Paragraph IV (Patent) Challenges for AVEED
Drugname Dosage Strength RLD Date
➤ Subscribe Injection 250 mg/mL ➤ Subscribe ➤ Try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
Cantor Fitzgerald
Argus Health
Covington
McKesson
QuintilesIMS

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.